IGKV2D-24 and schizophrenia: Since α7 receptors modulate hippocampal activity (through release of glutamate and GABA) and α7 agonists and positive allosteric modulators can restore cognitive performance in a number of preclinical models for Alzheimer's disease [46] and schizophrenia [47], it would be interesting to investigate the effects of α7 agonists in diabetic rats in future studies.